In a patient with systemic lupus erythematosus who develops a hypersensitivity reaction to a skin‑prick test and reports neuropathy, what is the likely cause and what management is recommended?

Peripheral Neuropathy in Lupus: Likely Cause and Management

In a lupus patient with neuropathy and hypersensitivity to skin prick testing, the neuropathy is most likely caused by inflammatory neuropsychiatric lupus (NPSLE) affecting the peripheral nervous system, and should be treated with immunosuppressive therapy—specifically glucocorticoids combined with cyclophosphamide or other immunosuppressants.

Understanding the Clinical Picture

The combination of neuropathy and hypersensitivity reactions in an SLE patient points to two distinct but related issues:

The Neuropathy Component

Peripheral neuropathy in SLE is an inflammatory neuropsychiatric manifestation that occurs in 1-5% of lupus patients 1. When peripheral neuropathy develops in lupus, it represents active inflammatory disease affecting the peripheral nervous system and qualifies as a major neuropsychiatric manifestation requiring aggressive treatment 2.

The neuropathy can manifest as:

• Sensory ganglionopathy (dorsal root ganglion involvement) with non-length-dependent sensory loss 3, 4
• Axonal sensorimotor neuropathy with both motor and sensory deficits 5, 6
• Acute or subacute onset distinguishing it from chronic metabolic neuropathies 3

The Hypersensitivity Component

The hypersensitivity reaction to skin prick testing reflects the underlying immune dysregulation in SLE. Recent evidence demonstrates that autoreactive IgE and altered Fc receptor signaling contribute to both allergic and autoimmune processes in lupus 7. This is not coincidental—it represents the same immune dysfunction driving the disease.

Diagnostic Approach

The workup should mirror that for any patient with peripheral neuropathy, but with lupus-specific considerations 2, 1:

• Nerve conduction studies and EMG to characterize the neuropathy pattern (axonal vs. demyelinating, sensory vs. motor) 3, 4
• Assess lupus disease activity: Check anti-dsDNA, complement levels (C3/C4), inflammatory markers 2
• Rule out other causes: Exclude infection, metabolic causes, medication toxicity
• Consider antiphospholipid antibodies as they are strong risk factors for neuropsychiatric manifestations 1

Treatment Recommendations

For Inflammatory Peripheral Neuropathy

SLE patients with peripheral neuropathy considered to be of inflammatory origin benefit from immunosuppressive therapy 2. The treatment algorithm is:

1. Initial therapy: High-dose glucocorticoids (typically intravenous methylprednisolone 500-1000mg daily for 3-5 days, then oral prednisone) 5, 6

2. Add immunosuppressive agent:

   • Cyclophosphamide is the traditional first-line agent for severe neuropsychiatric lupus 5, 6
   • Alternative: Mycophenolate mofetil or azathioprine for less severe cases or when cyclophosphamide is contraindicated 2
   • Emerging option: Telitacicept showed complete resolution of neuropathy symptoms in a recent case, offering a steroid-sparing alternative particularly valuable for young women concerned about cyclophosphamide's gonadal toxicity 8

3. Consider adjunctive therapies:

   • Intravenous immunoglobulin (IVIG) may be beneficial, particularly in acute presentations 4, 6
   • Plasmapheresis for refractory cases 5
   • Rituximab for severe, treatment-resistant disease 9

For Hypersensitivity Manifestations

The hypersensitivity reactions require careful medication selection:

• Avoid known triggers and document all hypersensitivity reactions 9
• Consider biologics like omalizumab or dupilumab if allergic symptoms are prominent and interfere with treatment 7
• Screen for cutaneous lupus as this may predispose to drug hypersensitivity reactions 9

Critical Pitfalls to Avoid

1. Don't delay immunosuppression: Peripheral neuropathy in lupus can progress rapidly and cause permanent disability if not treated promptly 3, 5, 6

2. Don't attribute neuropathy to other causes without proper workup: While diabetic or uremic neuropathy may coexist, the acute/subacute onset and presence of active lupus strongly suggest inflammatory etiology 1

3. Don't use IVIG alone: While IVIG may provide temporary benefit, definitive treatment requires sustained immunosuppression 5, 4

4. Monitor for treatment response: Failure to improve by 3-6 months should prompt intensification of therapy 2, 8

5. Address the hypersensitivity: Multiple drug hypersensitivities may complicate standard immunosuppression and require individualized approaches, potentially including biologics 9

Expected Outcomes

With appropriate immunosuppressive therapy:

• Symptom improvement typically begins within weeks to months 8, 5
• Electrophysiological improvement may lag behind clinical improvement by several months 8, 4
• Complete resolution is possible with early aggressive treatment 8, 3
• Delayed treatment risks permanent neurological sequelae 3, 6

The key principle: Peripheral neuropathy in lupus is a major organ manifestation requiring the same aggressive immunosuppression as lupus nephritis or CNS lupus 2, 1. The presence of hypersensitivity reactions complicates but does not contradict this approach—it simply requires more careful medication selection and potentially earlier use of biologic agents.